Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Gains from Investment Securities: 2020-2025

Historic Gains from Investment Securities for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to $2.0 million.

  • Biofrontera's Gains from Investment Securities rose 192.69% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 134.41%. This contributed to the annual value of $1.4 million for FY2024, which is 1265.74% up from last year.
  • As of Q3 2025, Biofrontera's Gains from Investment Securities stood at $2.0 million, which was up 1,400.84% from -$153,000 recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's Gains from Investment Securities peaked at $603.9 million during Q1 2022, and registered a low of -$5.4 million during Q2 2024.
  • Its 3-year average for Gains from Investment Securities is -$560,979, with a median of -$351,000 in 2024.
  • Within the past 5 years, the most significant YoY rise in Biofrontera's Gains from Investment Securities was 60,389,500.00% (2022), while the steepest drop was 268,650.00% (2022).
  • Over the past 5 years, Biofrontera's Gains from Investment Securities (Quarterly) stood at $12.8 million in 2021, then crashed by 108.76% to -$1.1 million in 2022, then slumped by 297.41% to -$4.5 million in 2023, then surged by 92.12% to -$351,000 in 2024, then soared by 192.69% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, -$153,000 for Q2 2025, and -$548,000 during Q1 2025.